Primary treatment choice and response to treatment in aggressive retinopathy of prematurity (ROP)
| Parameter | Bevacizumab injection (7 eyes) | Ranibizumab injection (33 eyes) | Laser ablation (5 eyes) |
| ROP zone at primary treatment | |||
| Zone I | 1 eyes | 19 eyes | none |
| Posterior zone II | 2 eyes | 4 eyes | none |
| Zone II | 4 eyes | 10 eyes | 5 eyes |
| PMA at primary treatment, weeks | 36.3±2.7 | 36.3±2.8 | 39.2±5.9 |
| Anti-VEGF injection dose and numbers | |||
| B 0.625 mg 5 eyes | R 0.25 mg 9 eyes | none | |
| B 0.5 mg 2 eyes | R 0.2 mg 16 eyes | ||
| R 0.1 mg 8 eyes | |||
| Periods of plus disease disappearance after primary treatment, days | 47.6±12.7 | 22.1±25.8 ~ not disappear | 20.2±11.3 |
| Additional treatment-requiring eyes | 2 eyes (28.58%) | 21 eyes (63.64%) | 2 eyes (40.00%) |
| Duration of additional treatment after primary treatment, days | 18 | 62.3±40.9 | 13 |
Values of gestational age, birth weight, PMA at primary treatment, periods of plus disease disappearance and duration of additional treatment each subgroup are presented as mean±SD.
anti-VEGF, antivascular endothelial growth factor; B, bevacizumab; PMA, postmenstrual age; R, ranibizumab.